NSCLC
Conditions
Keywords
KN046, Axitinib, neoadjuvant
Brief summary
Evaluation of the efficacy of KN046 combined with acitinib as a neoadjuvant therapy for resectable NSCLC through primary pathological response rate and surgical resection rate
Detailed description
The purpose of this study is to evaluate the rate of major pathological remission (MPR) with preoperative use of KN046 versus axitinib, and thus to assess the efficacy of KN046 in combination with axitinib in patients with Stage IB-IIIB (Stage IIIB only T3N2M0) NSCLC (according to the 8th edition of the AJCC classification) who are scheduled to undergo surgery. Eligible subjects for this study were candidates for surgery for resectable stage IB-IIIB (stage IIIB only T3N2M0) NSCLC as judged by the investigator, with no evidence of distant metastases as assessed, and no evidence of unresectable local regional tumour extension.
Interventions
DRUGKN046 plus Axitinib
KN046 combined with axitinib as a neoadjuvant treatment regimen
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The subject is at least 18 years old and\<75 years old on the day of signing the informed consent form, regardless of gender, and is willing to follow the research procedure; 2. Confirmed by histology or cytology as non-small cell lung cancer; 3. NSCLC patients evaluated by researchers as resectable in stage IB-IIIB (stage IIIB only limited to T3N2M0) (AJCC 8th edition); 4. Has not received any anti-tumor treatment in the past, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy; 5. No allergenic EGFR mutation or ALK change; 6. The ECOG score is 0-1 points.
Exclusion criteria
1. The lesion of squamous non-small cell lung cancer presents as a central type of lung cancer accompanied by cavity formation or invasion of blood vessels, with a high risk of hemoptysis; 2. Previously or currently suffering from interstitial pneumonia/lung disease that requires systemic hormone therapy; 3. Previous history of allogeneic bone marrow or organ transplantation; 4. Subjects who have undergone major surgical treatment (such as abdominal or thoracic surgery; excluding diagnostic puncture or peripheral vascular pathway replacement surgery) or have not recovered from surgical treatment within 28 days before the administration of this trial; 5. Prior to allocation, they have received systemic anti-cancer treatment, including research drugs targeting current malignant tumors; 6. Other known malignant tumors are progressing or require active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding bladder carcinoma in situ) who have received possible radical treatment are not excluded; 7. Pregnant and/or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MPR | one month within postsurgery | MPR is defined as the presence of ≤ 10% of active tumor cells in postoperative pathology (primary lesion). |
| Surgical resection rate | six weeks after last cycle of neoadjuvant therapy | Surgical resection rate: refers to the proportion of subjects who completed the surgery according to the plan, defined as the distance from the last neoadjuvant treatment administration, and the surgical time ≤ 6 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complication rate | three months within postsurgery | The incidence and severity of AE (classified according to CTCAE v5.0), severity, and their relationship with experimental treatment; Any abnormal results of laboratory tests, vital signs, and physical examinations; |
| pCR | one month within postsurgery | PCR is defined as postoperative pathology (primary lesion) showing the absence of viable tumor cells |
| ORR | one month within postsurgery | Defined as the proportion of subjects who achieved complete remission (CR) or partial remission (PR) according to RECIST 1.1 |
Countries
China
Contacts
Primary ContactChang Chen, Dr
Outcome results
None listed